Vivozon is evolving into a total healthcare group capable of developing new drugs and producing and selling finished drugs, together with Vivozon Pharmaceutical. Vivozon US and Vivozon Canada are U.S. and Canadian subsidiaries of Vivozon, which are smoothly conducting global clinical trials and engaging in overseas cooperation for non-narcotic analgesics. Clairvoyant Ventures, a 100% subsidiary of Vivozon, has a differentiated portfolio and investment capabilities in the bio-healthcare field and operates an investment union worth approximately KRW 65 billion.